Hot melt extrusion (HME) is frequently used for amorphous solid dispersion preparation and subsequent solubility and bioavailability improvement of poorly water-soluble drugs. This technique can generate numerous structures, including granules, pallets, and filaments, according to the requirement. The present study investigates the fundamental factors affecting the properties of etoricoxib-Soluplus filaments prepared by the HME method for additive manufacturing applications. The theoretical and experimental understanding of the drug−polymer miscibility was evaluated initially. Further, a detailed investigation was done to understand the role of process and formulation variables on the quality and performance of the extruded filaments. Characterization of filaments was done by Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and differential scanning calorimetry (DSC). The mechanical properties and ductility of the filaments were evaluated by texture analysis, tensile strength, and X-ray microcomputed tomography (μCT). The in vitro drug release study was performed to understand the release characteristics of the filaments. Further, the filaments were subjected to the feedability and printability study, which showed promising filament characteristics suitable for printing by the fused deposition modeling (FDM) technique. In a broader sense, such HME-based filaments, which are mostly amorphous solid dispersion in nature, can readily be used as printing ink for instant printing of personalized medicines of those drugs, which can withstand the conditions of hot melt extrusion, and FDMbased three-dimensional (3D) printing. Thus, the etoricoxib filament preparation method reported herein can be a promising approach for 3D printing applications and etoricoxib personalized therapy.